Promising combo therapy for aggressive brain cancer enters final testing phase

NCT ID NCT06419946

Recruiting now Disease control Sponsor: Vastra Gotaland Region Source: ClinicalTrials.gov ↗

First seen Apr 14, 2026 · Last updated Jun 21, 2026 · Updated 13 times

Summary

This Phase 3 trial tests whether adding lomustine to standard temozolomide chemotherapy improves survival for people with newly diagnosed glioblastoma that has a specific genetic marker (MGMT methylated). About 200 adults aged 18-70 will be randomly assigned to receive either the standard drug alone or the two-drug combination, starting with radiation. Researchers will track survival, tumor progression, side effects, and quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Aarhus University Hospital
RECRUITING

Aarhus, Denmark

Contact Email: •••••@•••••
Gävle Hospital
RECRUITING

Gävle, Sweden

Contact Email: •••••@•••••
Haukeland University Hospital
RECRUITING

Bergen, Norway

Contact Email: •••••@•••••
Kalmar Country Hospital
RECRUITING

Kalmar, Sweden

Contact Email: •••••@•••••
Karolinska Institutet
ENROLLING_BY_INVITATION

Stockholm, Sweden
Kepler University Hospital
RECRUITING

Linz, Austria

Contact Email: •••••@•••••
Medizinische Universität Innsbruck
NOT_YET_RECRUITING

Innsbruck, Austria

Contact Email: •••••@•••••
Norrlands Universitetssjukhus, Umea, Sweden
RECRUITING

Umeå, Sweden

Contact Email: •••••@•••••
Oslo University Hospital
RECRUITING

Oslo, Norway

Contact Email: •••••@•••••
Ryhov County Hospital
RECRUITING

Jönköping, Sweden

Contact Email: •••••@•••••

Contact
Sahlgrenska University Hospital
RECRUITING

Gothenburg, Sweden

Contact Email: •••••@•••••
Skåne University Hospital
NOT_YET_RECRUITING

Lund, Sweden

Contact Email: •••••@•••••
Sorlandet Sykehus
RECRUITING

Kristiansand, Norway

Contact Email: •••••@•••••
St Olavs Hospital
NOT_YET_RECRUITING

Trondheim, Norway

Contact Email: •••••@•••••
Stavanger University Hospital
NOT_YET_RECRUITING

Stavanger, Norway

Contact Email: •••••@•••••
Sundsvall Hospital
ENROLLING_BY_INVITATION

Sundsvall, Sweden
University Hospital Graz
NOT_YET_RECRUITING

Graz, Austria

Contact Email: •••••@•••••
University Hospital St. Pölten
ENROLLING_BY_INVITATION

Sankt Pölten, Austria
Uppsala University Hospital
RECRUITING

Uppsala, Sweden

Contact Email: •••••@•••••
Örebro University Hospital
RECRUITING

Örebro, Sweden

Contact Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Temozolomide and lomustine (chemotherapy pills)

What this could lead to

If successful, this combination could extend survival for people with a specific type of glioblastoma, offering a new standard treatment option.

What could go wrong

This is an early-stage Phase 3 trial with only 200 participants. The combination may cause more side effects than standard therapy, and results may not apply to all glioblastoma patients.

Conditions

The condition(s) this trial relates to.

glioblastoma IDH-wildtype glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA, IDH-WILDTYPE GLIOBLASTOMA, IDH-WILDTYPE MGMT-METHYLATED GLIOBLASTOMA MGMT-METHYLATED GLIOBLASTOMA